These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25781980)

  • 1. HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?
    Marra CM
    Antivir Ther; 2015; 20(4):365-7. PubMed ID: 25781980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
    Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
    Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
    Letendre S; Marquie-Beck J; Capparelli E; Best B; Clifford D; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Morgello S; Simpson D; Grant I; Ellis RJ;
    Arch Neurol; 2008 Jan; 65(1):65-70. PubMed ID: 18195140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.
    Smurzynski M; Wu K; Letendre S; Robertson K; Bosch RJ; Clifford DB; Evans S; Collier AC; Taylor M; Ellis R
    AIDS; 2011 Jan; 25(3):357-65. PubMed ID: 21124201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.
    Cross HM; Combrinck MI; Joska JA
    S Afr Med J; 2013 Sep; 103(10):758-62. PubMed ID: 24079630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
    Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
    Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S
    Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.
    Casado JL; Marín A; Moreno A; Iglesias V; Perez-Elías MJ; Moreno S; Corral I
    J Neurovirol; 2014 Feb; 20(1):54-61. PubMed ID: 24420449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Antiretroviral Medication Neuropenetrance and Neurocognitive Outcomes in HIV+ Adults: A Review of the Literature Examining the Central Nervous System Penetration Effectiveness Score.
    Arentoft A; Troxell K; Alvarez K; Aghvinian M; Rivera Mindt M; Cherner M; Van Dyk K; Razani J; Roxas M; Gavilanes M
    Viruses; 2022 May; 14(6):. PubMed ID: 35746623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs.
    Reddy YS; Kashuba A; Gerber J; Miller V;
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):167-76. PubMed ID: 12689408
    [No Abstract]   [Full Text] [Related]  

  • 14. Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score.
    Kahouadji Y; Dumurgier J; Sellier P; Lapalus P; Delcey V; Bergmann J; Hugon J; Paquet C
    HIV Med; 2013 May; 14(5):311-5. PubMed ID: 23035982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Central Nervous System Penetration Effectiveness of Highly Active Antiretroviral Therapy on Neuropsychological Performance and Neuroimaging in HIV Infected Individuals.
    Baker LM; Paul RH; Heaps-Woodruff JM; Chang JY; Ortega M; Margolin Z; Usher C; Basco B; Cooley S; Ances BM
    J Neuroimmune Pharmacol; 2015 Sep; 10(3):487-92. PubMed ID: 25900078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.
    Caniglia EC; Cain LE; Justice A; Tate J; Logan R; Sabin C; Winston A; van Sighem A; Miro JM; Podzamczer D; Olson A; Arribas JR; Moreno S; Meyer L; del Romero J; Dabis F; Bucher HC; Wandeler G; Vourli G; Skoutelis A; Lanoy E; Gasnault J; Costagliola D; Hernán MA;
    Neurology; 2014 Jul; 83(2):134-41. PubMed ID: 24907236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
    Marra CM; Zhao Y; Clifford DB; Letendre S; Evans S; Henry K; Ellis RJ; Rodriguez B; Coombs RW; Schifitto G; McArthur JC; Robertson K;
    AIDS; 2009 Jul; 23(11):1359-66. PubMed ID: 19424052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
    Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.